Literature DB >> 33563956

Off-label therapy targeting pathogenic inflammation in COVID-19.

Luigina Romani1, Carlo Tomino2, Paolo Puccetti3, Enrico Garaci4.   

Abstract

Year:  2020        PMID： 33563956     DOI： 10.1038/s41420-020-0283-2

Source DB:  PubMed          Journal:  Cell Death Discov        ISSN： 2058-7716


× No keyword cloud information.
  2 in total

1.  Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Authors:  Marc Feldmann; Ravinder N Maini; James N Woody; Stephen T Holgate; Gregory Winter; Matthew Rowland; Duncan Richards; Tracy Hussell
Journal:  Lancet       Date:  2020-04-09       Impact factor: 79.321

2.  Programmed cell death 4 modulates lysosomal function by inhibiting TFEB translation.

Authors:  Xiaotong Chen; Yetong Guan; Yi Zhang; Yufeng Jia; Wen Li; Chun Guo; Yuan Li; Xiaoyan Wang; Yongyu Shi; Qun Wang; Faliang Zhu; Yan Li; Lining Zhang
Journal:  Cell Death Differ       Date:  2020-10-25       Impact factor: 15.828
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.